Across TCGA pan-cancer cohorts, LINC02514 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of LINC02514’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where LINC02514 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC02514 is over-expressed in tumor.
PRAD are the cancer types where LINC02514 tumor–normal differential expression is most reproducible.